
Vitality · 99%+ purity
Retatrutide is a triple agonist peptide that acts on GLP-1, GIP, and glucagon receptors, representing the new generation of metabolic therapy. It supports potent weight management and improved cardiometabolic markers.
Scientific Profile
Size
10 mg
Purity
99%+
Available Sizes & Pricing
10 mg — $85 USD · $120 CAD · ₡40,000 CRC · 20 mg — $120 USD · $160 CAD · ₡55,000 CRC · 30 mg — $160 USD · $190 CAD · ₡70,000 CRC · 40 mg — $190 USD · $220 CAD · ₡90,000 CRC
Key Benefits
SHIPS TO COSTA RICA · PANAMA
JANOSHIK
Research Chemicals
PURA VIDA SCIENCE
puravidapeptidescience.com
For Research Use Only

| TEST | SPECIFICATION | RESULT | METHOD |
|---|---|---|---|
| Appearance | Loose white or almost white powder | Loose white powder | Visual |
| Solubility | Soluble in water | Conforms | Visual |
| Solution Clarity and Color | Clear and colorless (C=30 mg/ml) | Conforms | Visual |
| Identification (HPLC) | Main peak conforms | Conforms | HPLC |
| Mass Spectrum | 4731.4 ± 1.0 | 4731.1 | MS |
| Related Substances (HPLC) | Largest: NMT 0.5% / Total: NMT 2.0% | 0.17% / 0.78% | HPLC |
| Purity (HPLC) | NLT 98.0% | 99.2% | HPLC |
| pH | 6.5–8.5 | 7.3 | pH Meter |
| Acid Group Ions (TFA/Acetate) | NMT 0.5% | N.D | Ion Chrom. |
| Water Content (KF) | NMT 8.0% | 3.8% | KF |
| Sodium Ion | 1.0–2.0% | 1.6% | ICP-MS |
| Peptide Content | NLT 90.0% | 93.7% | Assay |
| Oligomer | NMT 0.5% | N.D | SEC |
| Residual Solvent | All solvents NMT limits | Conforms | GC |
| Bacterial Endotoxins | NMT 5 EU/mg | <3 EU/mg | LAL |
| Microbial Limits | Total aerobes ≤100 cfu/g / Mold and Yeast ≤10 cfu/g | Conforms | Micro |
| Assay | 95.0%–105.0% | 99.0% | Assay |
| Peptide Sequence | Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(PEG2-γ-Glu-Ácido eicosanodioico)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ | Conforms | LC-MS/MS |
HPLC Chromatogram
Purity: 99.2%
LC-MS Spectrum
Observed Mass: 4731.1 Da
Approved By:
Quality Control
Quality Approved
Date:
Mar 15, 2026
COA ID:
JRC-COA-RET26031501